Skip to main content

Table 5 Univariate and multivariate analyses for OS of ovarian cancer

From: Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients

Variable n (%) Median (months) p value
Age:
 <70 118 (94.4 %) 46.0 0.022
 ≥70 7 (5.6 %) 14.8
Performance status WHO:
 ▪ 0 19 (15.2 %) NR 0.28
 ▪ Other 106 (84.8) 36.2  
FIGO stage:
 ▪ Early (I,II) 24 (19.2 %) NR 0.003
 ▪ Advanced (III, IV) 101 (80.8 %) 33.3  
Chemotherapy regimen:
 ▪ With paclitaxel 113 (90.4 %) 46.1 0.035
 ▪ Without paclitaxel 12 (9.6 %) 16.6  
Chemotherapy regimen:
 ▪ With cisplatin 55 (44.0 %) 50.5 0.24
 ▪ With carboplatin 70 (56.0 %) 32.3  
Type of histology:
 ▪ Serous 68 (54.4 %) 33.2 0.047
 ▪ Other 57 (45.6 %) NR  
Grading:
 ▪ 1 and 2 45 (36.0 %) 49.8 0.53
 ▪ 3 and unspecified 80 (64.0 %) 35.6  
Primary surgery:
 ▪ Optimal (<1 cm) 77 (61.6 %) 51.8 0.028
 ▪ Suboptimal (>1 cm) 48 (38.4 %) 30.0  
BRCA1 status:
 ▪ Wild type 108 (86.4 %) 35.6 0.041
 ▪ Germline mutation 17 (13.6 %) NR  
Multivariate analysis
Variable HR (95 % CI) p value
Age:
 <70 0.15 (0.053 – 0.417) < 0.001
 ≥70
Primary surgery:
 ▪ Optimal (<1 cm) 0.39 (0.205 – 0.715) 0.003
 ▪ Suboptimal (>1 cm)
BRCA1 status:
 ▪ Germline mutation 0.14 (0.032 – 0.650) 0.012
 ▪ Wild type
  1. NR not reached